EMD Millipore Introduces Parteck® SRP 80 Excipient for Sustained-Release Oral Solid Dose Formulations
BILLERICA, Mass., Oct. 26, 2015 /PRNewswire/ — EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, Germany, today introduced Parteck® SRP 80, a new functional excipient for oral sustained-release formulations. Parteck® SRP 80 is a polyvinyl alcohol (PVA) based excipient specifically designed for modified-release applications, for optimization of pharmacokinetics and pharmacodynamics as well as the bioavailability of actives. The new excipient is fully synthetic, ensuring batch-to-batch and performance consistency and facilitating quality by design (QbD) and validation processes.